{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:19:05Z","timestamp":1789993145420,"version":"4.0.1"},"reference-count":28,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T00:00:00Z","timestamp":1032134400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2002,9]]},"abstract":"<jats:p> <jats:bold>BACKGROUND<\/jats:bold> : Recipient exposure to allogeneic donor WBCs results in transfusion complications for selected populations of recipients. Whether or not WBC reduction should be universally applied is highly controversial.<\/jats:p><jats:p> <jats:bold>STUDY DESIGN AND METHODS<\/jats:bold> : In a general hospital, a randomized, controlled clinical trial of conversion to universal WBC reduction was conducted. Patients (11%) with established medical indications for WBC\u2010reduced blood were not eligible. All other patients who required transfusion were assigned at random to receive either unmodified blood components or stored WBC\u2010reduced RBCs and platelets. Analysis for each patient was restricted to the first hospitalization.<\/jats:p><jats:p> <jats:bold>RESULTS<\/jats:bold> : All eligible patients (n = 2780) were enrolled. Three specified primary outcome measures were not different between the two groups: 1) in\u2010hospital mortality (8.5% control; 9.0% WBC\u2010reduced; OR, 0.94 [95% CI, 0.72\u20101.22]; p = 0.64); 2) hospital length of stay (LOS) after transfusion (median number of days, 6.4 for control and 6.3 for WBC\u2010reduced; p = 0.21); and 3) total hospital costs (median, $19,500 for control and $19,200 for WBC\u2010reduced, p = 0.24). Secondary outcomes (intensive care LOS, postoperative LOS, antibiotic usage, and readmission rate) were not different between the two groups. Subgroup analysis based on patient age, sex, amount of blood transfused, or category of surgical procedure showed no effect of WBC reduction. Patients who received WBC\u2010reduced blood had a lower incidence of febrile reactions (p = 0.06).<\/jats:p><jats:p> <jats:bold>CONCLUSION<\/jats:bold> : A beneficial effect of conversion from selective to universal WBC reduction was not demonstrated.<\/jats:p>","DOI":"10.1046\/j.1537-2995.2002.00182.x","type":"journal-article","created":{"date-parts":[[2002,10,9]],"date-time":"2002-10-09T15:18:58Z","timestamp":1034176738000},"page":"1114-1122","source":"Crossref","is-referenced-by-count":129,"title":["A prospective, randomized clinical trial of universal WBC reduction"],"prefix":"10.1111","volume":"42","author":[{"given":"W.H.","family":"Dzik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.K.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Kalish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Stowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,9,16]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1999.39399219278.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","unstructured":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group.N Engl J Med1997;337:1861\u20109.","DOI":"10.1056\/NEJM199712253372601"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","article-title":"A comparison of filtered leukocyte\u2010reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion\u2010associated CMV infection after marrow transplant.","volume":"86","author":"Bowden RA","year":"1995","journal-title":"Blood"},{"key":"e_1_2_6_5_2","unstructured":"Vamvakas EC Blajchman MA editors. Immunomodulatory effects of blood transfusion. Bethesda: American Association of Blood Banks; 1999."},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800790613"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92247-Q"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)06168-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.6.562"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199305133281902"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91965-8"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(98)00245-1"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s003840100298"},{"issue":"1","key":"e_1_2_6_14_2","first-page":"35a","article-title":"Effects of leukocyte\u2010depletion of blood transfusions in cardiac surgery: a prospective randomized trial (abstract).","volume":"8","author":"Van De Watering L","year":"2001","journal-title":"Transfus Clin Biol"},{"key":"e_1_2_6_15_2","first-page":"S551","article-title":"Impact of leukoreduced red blood cells (LR RBC) on length of stay (LOS) in surgical patients cost\u2010justifies universal leukocyte reduction (abstract).","volume":"39","author":"Newsome JL","year":"1999","journal-title":"Transfusion"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200203000-00010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40060751.x"},{"key":"e_1_2_6_18_2","unstructured":"College of American Pathologists policy on universal leukoreduction. Available from: URL:http:\/\/cap.org\/html\/lip\/transmed\/Leukoreduction.doc"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33593255602.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1996.36196190510.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(00)80114-5"},{"key":"e_1_2_6_22_2","unstructured":"Nightingale S. Advisory Committee on Blood Safety & Availability. Bloodsafety Summary\u2014January 2001. Washington DC: U.S. Department of Health and Human Services; 2001. Available from: URL:http:\/\/www.hhs.gov\/bloodsafety\/summaries\/sumjan01.html"},{"key":"e_1_2_6_23_2","unstructured":"Ratko TA. Technology assessment: leukocyte\u2010reduced cellular blood components. Oak Brook IL: University HealthSystem Consortium; 2001."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41050691.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood.V80.8.2128.2128","article-title":"Allogeneic leukocytes but not therapeutic blood elements induce reactivation and dissemination of latent human immunodeficiency virus type I infection: implications for transfusion support of infected patients.","volume":"80","author":"Busch MP","year":"1992","journal-title":"Blood"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.12.1592"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.9.1859"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2168.2001.01674.x"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood.V93.5.1770.405a14_1770_1777","article-title":"Soluble HLA Class I, HLA Class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusion.","volume":"93","author":"Ghio M","year":"1999","journal-title":"Blood"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1537-2995.2002.00182.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2002.00182.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1046\/j.1537-2995.2002.00182.x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1537-2995.2002.00182.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:30:24Z","timestamp":1694421024000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1537-2995.2002.00182.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["10.1046\/j.1537-2995.2002.00182.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1537-2995.2002.00182.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}